OMER
NASDAQOmeros Corporation
Website
News25/Ratings12
News · 26 weeks27+100%
2025-10-262026-04-19
Mix1390d
- Other7(54%)
- Earnings2(15%)
- SEC Filings2(15%)
- Insider1(8%)
- Leadership1(8%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Omeros CorporationSCHEDULE 13G/A - OMEROS CORP (0001285819) (Subject)
- PRSagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerSAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. "We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development
- PRCMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)– Permanent, product-specific J-code facilitates efficient claims and reimbursement – Omeros Corporation (NASDAQ:OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026. "For patients with TA-TMA, access to effective treatment without unnecessary delay is critical," said Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer of Omeros. "
- SECSEC Form 10-K filed by Omeros Corporation10-K - OMEROS CORP (0001285819) (Filer)
- SECOmeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OMEROS CORP (0001285819) (Filer)
- PROmeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Omeros CorporationSCHEDULE 13G/A - OMEROS CORP (0001285819) (Subject)
- PROmeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Inves
- PROmeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA TreatmentOmeros Corporation (NASDAQ:OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled "Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy," will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôpital Saint-Antoine, AP-HP, and will feature speakers Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, and Michelle L. Schoettler, MD, MS, Children's Healthcare of Atlanta. The EBMT Annual Meeting is a key eve
- INSIDERChairman, CEO & President Demopulos Gregory A Md exercised 400,000 shares at a strike of $10.27 and covered exercise/tax liability with 357,678 shares, increasing direct ownership by 3% to 1,469,308 units (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- PROmeros Announces Successful Primate Study in OncotoX-AML™ Drug Program— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients — Omeros Corporation (NASDAQ:OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros' OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired
- SECSEC Form SCHEDULE 13G filed by Omeros CorporationSCHEDULE 13G - OMEROS CORP (0001285819) (Subject)
- PROmeros Announces First Commercial Sales of YARTEMLEA®— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — Omeros Corporation (NASDAQ:OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpatient settings. YARTEMLEA is the first and only approved therapy for
- INSIDERVP, Finance & CAO Borges David J. sold $750,915 worth of shares (60,000 units at $12.52) and exercised 30,000 shares at a strike of $3.06, closing all direct ownership in the company (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- SECOmeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition8-K - OMEROS CORP (0001285819) (Filer)
- SECOmeros Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - OMEROS CORP (0001285819) (Filer)
- PROmeros Announces New Date for YARTEMLEA® Approval Conference Call— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th
- PRFDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET – First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno
- SECOmeros Corporation filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits8-K - OMEROS CORP (0001285819) (Filer)
- PROmeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)Omeros Corporation (NASDAQ:OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complement system – and has shown multiple potential advantages over other alternative pathway inhibitors in development or on the market. The transaction was completed pursuant to an asset purchase and license agreement that was announced on October 15, 2025. Omeros is eligible to receive upfront and near-term milestone payments up
- SECSEC Form 424B5 filed by Omeros Corporation424B5 - OMEROS CORP (0001285819) (Filer)
- SECSEC Form S-3ASR filed by Omeros CorporationS-3ASR - OMEROS CORP (0001285819) (Filer)
- SECSEC Form 10-Q filed by Omeros Corporation10-Q - OMEROS CORP (0001285819) (Filer)
- PROmeros Corporation Reports Third Quarter 2025 Financial Results– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include: Net loss for the third quarter of 2025 was $30.9 million, or $0.47 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024. For the nine months ended September 30, 2025, our net loss was $89.8 million, or $1.47 per share, compared to a net loss of $125.5 million, or $2.15 per share in the corresponding prior year period. Non-GAAP adjusted net loss for the three months and nine months ended September 30, 2025 was $22.1 million, or
- SECOmeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OMEROS CORP (0001285819) (Filer)